Condition: Chronic Obstructive Pulmonary Disease · Sponsor: Meribank Biotech Co., Ltd.
This phase II study is a randomized, placebo-controlled, double-blind study to evaluate the safety and efficacy of UMC119-06-05 compared to placebo in treating subjects with moderate to severe COPD. Eligible subjects will receive a single-dose IV infusion of UMC119-06-05 or placebo.
This description comes directly from the study's public registry record.
Ray Chang, Ph.D. · +886-2-8978-7777 · ray.chang@meribank.com.tw
Joseph Chen, Ph.D. · +886-2-8978-7777 · joseph.chen@meribank.com.tw
Always discuss trial participation with your own doctor first.
| Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare | New Taipei City, Taiwan | Recruiting |
| Chang Gung Memorial Hospital, Linkou | Taoyuan City, Taiwan | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06491043